StockpollyBeta
Get App
Popularity #4,404
ATRA · NASDAQ · Biotechnology

Atara Biotherapeutics (ATRA)

Supports Pierre Fabre’s global EBV-targeted tab-cel program through a lean partner-led operating model.

$8.59
vs last close−0.34 (−3.81%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue242729403398183211
Cost of revenue3325872010000
Gross profit012524332678173100
69545742543839147445
Research & development5744463344292773001
12101191091164444
General & administrative1201191091164444
Other expenses000000010000
Operating income−70−53−31−18−22−12393−4−3−3−5
0−70−10−1−1−1−1−1−10
Interest income111001000000
Interest expense111111111110
Other non-operating income−16−10−1−1000000
Income before tax−70−60−32−19−22−13382−4−3−4−5
Income tax expense000000000000
Net income from continuing operations−70−60−32−19−22−13382−4−3−4−5
Net income−70−60−32−19−22−13382−4−3−4−5
EPS, basic−$16.40−$13.98−$5.65−$3.10−$2.93−$1.19$3.53$0.20−$0.32−$0.25−$0.29−$0.32
EPS, diluted−$16.40−$13.98−$5.65−$3.10−$2.93−$1.19$3.50$0.19−$0.32−$0.25−$0.29−$0.32
Weighted average shares, basic4466711111214131415
Weighted average shares, diluted4466711111214131415
EBITDA−67−58−29−16−20−11414−3−2−3−5
Depreciation & amortization111111200000
EBIT−68−59−31−18−21−12393−3−3−3−5